Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2005 2
2006 4
2007 6
2008 7
2009 4
2010 8
2011 6
2013 8
2014 5
2015 8
2016 6
2017 2
2018 3
2019 6
2020 4
2021 11
2022 16
2023 22
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Results by year

Filters applied: . Clear all
Page 1
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.
Baden D, Zukunft S, Hernandez G, Wolgast N, Steinhauser S, Pohlmann A, Schliemann C, Mikesch JH, Steffen B, Sauer T, Hanoun M, Schafer-Eckart K, Krause SW, Hanel M, Einsele H, Jost E, Brummendorf TH, Scholl S, Hochhaus A, Neubauer A, Burchert A, Kaufmann M, Niemann D, Schaich M, Blau W, Kiani A, Gorner M, Kaiser U, Kullmer J, Weber T, Berdel WE, Ehninger G, Muller-Tidow C, Platzbecker U, Serve H, Bornhauser M, Rollig C, Baldus CD, Fransecky L. Baden D, et al. Among authors: baldus cd. Haematologica. 2024 Apr 24. doi: 10.3324/haematol.2024.285225. Online ahead of print. Haematologica. 2024. PMID: 38654660 Free article.
Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
Röllig C, Schliemann C, Ruhnke L, Fransecky L, Heydrich BN, Hanoun M, Noppeney R, Schäfer-Eckart K, Wendelin K, Mikesch JH, Middeke JM, Reimann M, Fiebig F, Zukunft S, Wermke M, Serve H, Platzbecker U, Müller-Tidow C, Baldus CD, Bornhäuser M. Röllig C, et al. Among authors: baldus cd. Br J Haematol. 2024 Apr 9. doi: 10.1111/bjh.19436. Online ahead of print. Br J Haematol. 2024. PMID: 38593353
Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma.
Kroeze E, Iaccarino I, Kleisman MM, Mondal M, Beder T, Khouja M, Höppner MP, Scheijde-Vermeulen MA, Kester LA, Brüggemann M, Baldus CD, Cario G, Bladergroen RS, Garnier N, Attarbaschi A, Verdu-Amorós J, Sutton R, Macintyre EA, Scholten K, Arias Padilla L, Burkhardt B, Beishuizen A, den Boer ML, Kuiper RP, Loeffen JLC, Boer JM, Klapper W. Kroeze E, et al. Among authors: baldus cd. Blood. 2024 Apr 8:blood.2024023938. doi: 10.1182/blood.2024023938. Online ahead of print. Blood. 2024. PMID: 38588489
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.
Burmeister T, Ströh AS, Kehden B, Trautmann H, Meyer C, Marschalek R, Larghero P, Schwartz S, Steffen B, Spriewald B, Heinicke T, Jäkel N, Westermann J, Nachtkamp K, Viardot A, Topp MS, Neumann M, Baldus CD, Gökbuget N, Brüggemann M. Burmeister T, et al. Among authors: baldus cd. Leukemia. 2024 Mar 22. doi: 10.1038/s41375-024-02209-7. Online ahead of print. Leukemia. 2024. PMID: 38519799 No abstract available.
Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence.
Eckardt JN, Hahn W, Röllig C, Stasik S, Platzbecker U, Müller-Tidow C, Serve H, Baldus CD, Schliemann C, Schäfer-Eckart K, Hanoun M, Kaufmann M, Burchert A, Thiede C, Schetelig J, Sedlmayr M, Bornhäuser M, Wolfien M, Middeke JM. Eckardt JN, et al. Among authors: baldus cd. NPJ Digit Med. 2024 Mar 20;7(1):76. doi: 10.1038/s41746-024-01076-x. NPJ Digit Med. 2024. PMID: 38509224 Free PMC article.
Prognostic impact of CEBPA mutational subgroups in adult AML.
Georgi JA, Stasik S, Kramer M, Meggendorfer M, Röllig C, Haferlach T, Valk P, Linch D, Herold T, Duployez N, Taube F, Middeke JM, Platzbecker U, Serve H, Baldus CD, Muller-Tidow C, Haferlach C, Koch S, Berdel WE, Woermann BJ, Krug U, Braess J, Hiddemann W, Spiekermann K, Boertjes EL, Hills RK, Burnett A, Ehninger G, Metzeler K, Rothenberg-Thurley M, Dufour A, Dombret H, Pautas C, Preudhomme C, Fenwarth L, Bornhäuser M, Gale R, Thiede C. Georgi JA, et al. Among authors: baldus cd. Leukemia. 2024 Feb;38(2):281-290. doi: 10.1038/s41375-024-02140-x. Epub 2024 Jan 16. Leukemia. 2024. PMID: 38228680 Free PMC article.
Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
Bastian L, Beder T, Barz MJ, Bendig S, Bartsch L, Walter W, Wolgast N, Brändl B, Rohrandt C, Hansen BT, Hartmann AM, Iben K, Das Gupta D, Denker M, Zimmermann J, Wittig M, Chitadze G, Neumann M, Schneller F, Fiedler W, Steffen B, Stelljes M, Faul C, Schwartz S, Müller FJ, Cario G, Harder L, Haferlach C, Pfeifer H, Gökbuget N, Brüggemann M, Baldus CD. Bastian L, et al. Among authors: baldus cd. Blood. 2024 Apr 4;143(14):1391-1398. doi: 10.1182/blood.2023021752. Blood. 2024. PMID: 38153913 Free PMC article.
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.
Eckardt JN, Stasik S, Röllig C, Petzold A, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Hanoun M, Kaiser U, Kaufmann M, Rácil Z, Mayer J, Oelschlägel U, Berdel WE, Ehninger G, Serve H, Müller-Tidow C, Platzbecker U, Baldus CD, Dahl A, Schetelig J, Bornhäuser M, Middeke JM, Thiede C. Eckardt JN, et al. Among authors: baldus cd. Leukemia. 2023 Dec;37(12):2395-2403. doi: 10.1038/s41375-023-02061-1. Epub 2023 Oct 13. Leukemia. 2023. PMID: 37833543 Free PMC article.
Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification.
Eckardt JN, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Krug U, Wörmann B, Hiddemann W, Görlich D, Sauerland C, Steffen B, Einsele H, Neubauer A, Burchert A, Schäfer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hänel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Ruhnke L, Schetelig J, Middeke JM, Serve H, Baldus CD, Platzbecker U, Müller-Tidow C, Bornhäuser M, Herold T, Thiede C, Röllig C. Eckardt JN, et al. Among authors: baldus cd. Leukemia. 2023 Nov;37(11):2282-2285. doi: 10.1038/s41375-023-02016-6. Epub 2023 Sep 7. Leukemia. 2023. PMID: 37679502 Free PMC article. No abstract available.
Dominant T-cell Receptor Delta Rearrangements in B-cell Precursor Acute Lymphoblastic Leukemia: Leukemic Markers or Physiological γδ T Repertoire?
Kelm M, Darzentas F, Darzentas N, Kotrova M, Wessels W, Bendig S, Baldus CD, Lettau M, Gökbuget N, Kabelitz D, Brüggemann M, Chitadze G. Kelm M, et al. Among authors: baldus cd. Hemasphere. 2023 Sep 1;7(9):e948. doi: 10.1097/HS9.0000000000000948. eCollection 2023 Sep. Hemasphere. 2023. PMID: 37670805 Free PMC article. No abstract available.
123 results